Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)-Reference-Cited by-同舟云学术

Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)

Published:2012-09-11 Issue:1 Volume:13 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Farkowski Michal M,Maciag Aleksander,Dabrowski Rafal,Pytkowski Mariusz,Kowalik Ilona,Szwed Hanna

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/1745-6215-13-162.pdf

Reference27 articles.

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder I, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31: 2369-2429. Erratum in: Eur Heart J 2011, 32:1172

2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le-Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC, Priori SG, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart association task force on practice guidelines. Circulation. 2011, 123: e269-e367. 10.1161/CIR.0b013e318214876d.

3. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH: Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010, 106: 1277-1283. 10.1016/j.amjcard.2010.06.054.

4. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN: CRAFT Investigators: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004, 44: 2355-2361. 10.1016/j.jacc.2004.09.021.

5. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ: Atrial Arrhythmia Conversion Trial Investigators: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008, 117: 1518-1525. 10.1161/CIRCULATIONAHA.107.723866.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating;Pharmaceuticals;2022-03-20

2. ANTAZOLINE RENAISSANCE IN THE TREATMENT OF CARDIAC ARRHYTHMIA: A REVIEW;Acta Poloniae Pharmaceutica - Drug Research;2020-04-29

3. Anaphylaxis-induced atrial fibrillation and anesthesia: Pathophysiologic and therapeutic considerations;Annals of Cardiac Anaesthesia;2020

4. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation;Cochrane Database of Systematic Reviews;2019-09-04

5. Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent;Cardiovascular Therapeutics;2017-03-13